280
Participants
Start Date
December 27, 2023
Primary Completion Date
September 30, 2024
Study Completion Date
December 31, 2024
Isuzinaxib (APX-115)
Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
Placebo
Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
NOT_YET_RECRUITING
Florida Cardiovascular Research, Hialeah
NOT_YET_RECRUITING
Sarkis Clinical Trials, Ocala
RECRUITING
Kangwon National University Hospital, Chuncheon
NOT_YET_RECRUITING
Keimyung University Dongsan Hospital, Daegu
RECRUITING
Chungnam National University Hospital, Daejeon
NOT_YET_RECRUITING
Inje University Ilsan Paik Hospital, Goyang
RECRUITING
Chonnam National University Hospital, Gwangju
NOT_YET_RECRUITING
Seoul National University Bundang Hospital, Seongnam-si
NOT_YET_RECRUITING
Kangbuk Samsung Hospital, Seoul
NOT_YET_RECRUITING
Korea University Anam Hospital, Seoul
RECRUITING
Samsung Medical Center, Seoul
NOT_YET_RECRUITING
The Catholic University of Korea Seoul St. Mary's Hospital, Seoul
RECRUITING
The Catholic University of Korea St. Vincent's Hospital, Suwon
NOT_YET_RECRUITING
Ulsan University Hospital, Ulsan
Lead Sponsor
Aptabio Therapeutics, Inc.
INDIV